A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence.


Journal

Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067

Informations de publication

Date de publication:
10 2022
Historique:
revised: 07 07 2022
received: 12 04 2022
accepted: 09 07 2022
pubmed: 24 8 2022
medline: 21 10 2022
entrez: 23 8 2022
Statut: ppublish

Résumé

CYP2D6 substrates are among the most highly prescribed medications in teenagers and also commonly associated with serious adverse events. To investigate the relative contributions of genetic variation, growth, and development on CYP2D6 activity during puberty, healthy children and adolescents 7-15 years of age at enrollment participated in a longitudinal phenotyping study involving administration of 0.3 mg/kg dextromethorphan (DM) and 4-h urine collection every 6 months for 3 years (7 total visits). At each visit, height, weight, and sexual maturity were recorded, and CYP2D6 activity was determined as the urinary molar ratio of DM to its metabolite dextrorphan (DX). A total of 188 participants completed at least one visit, and 102 completed all seven study visits. Following univariate analysis, only CYP2D6 activity score (p < 0.001), urinary pH (p < 0.001), weight (p = 0.018), and attention-deficit/hyperactivity disorder (ADHD) diagnosis (p < 0.001) were significantly correlated with log(DM/DX). Results of linear mixed model analysis with random intercept, random slope covariance structure revealed that CYP2D6 activity score had the strongest effect on log(DM/DX), with model-estimated average log(DM/DX) being 3.8 SDs higher for poor metabolizers than for patients with activity score 3. A moderate effect on log(DM/DX) was observed for sex, and smaller effects were observed for ADHD diagnosis and urinary pH. The log(DM/DX) did not change meaningfully with age or pubertal development. CYP2D6 genotype remains the single, largest determinant of variability in CYP2D6 activity during puberty. Incorporation of genotype-based dosing guidelines should be considered for CYP2D6 substrates given the prevalent use of these agents in this pediatric age group.

Identifiants

pubmed: 35997001
doi: 10.1111/cts.13380
pmc: PMC9579386
doi:

Substances chimiques

Cytochrome P-450 CYP2D6 EC 1.14.14.1
Dextromethorphan 7355X3ROTS
Dextrorphan 04B7QNO9WS

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2514-2527

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD058556
Pays : United States

Informations de copyright

© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

Drug Metab Dispos. 2016 May;44(5):750-7
pubmed: 26965986
J Child Adolesc Psychopharmacol. 2021 Feb;31(1):33-45
pubmed: 33074724
Mol Pharmacol. 2014 Dec;86(6):727-35
pubmed: 25217496
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Drug Metab Dispos. 2006 Apr;34(4):563-9
pubmed: 16415111
J Clin Pharmacol. 2015 Nov;55(11):1207-17
pubmed: 26009792
Int Clin Psychopharmacol. 1999 Jan;14(1):1-18
pubmed: 10221637
Front Pharmacol. 2010 Oct 04;1:121
pubmed: 21833166
N Engl J Med. 2003 Sep 18;349(12):1157-67
pubmed: 13679531
Clin Pharmacol Ther. 2014 Sep;96(3):304-6
pubmed: 24926777
Mol Psychiatry. 2013 Mar;18(3):273-87
pubmed: 22565785
Clin Pharmacol Ther. 2007 Apr;81(4):510-6
pubmed: 17301735
Clin Pharmacol Ther. 2019 Jul;106(1):94-102
pubmed: 30801677
Clin Transl Sci. 2022 Oct;15(10):2514-2527
pubmed: 35997001
Pharmacogenomics. 2012 Jan;13(1):91-111
pubmed: 22111604
Clin Pharmacol Ther. 1999 Nov;66(5):535-41
pubmed: 10579482
Clin Pharmacol Ther. 2007 Feb;81(2):242-51
pubmed: 17259947
Pharmacogenomics. 2010 Jan;11(1):43-53
pubmed: 20017671
J Clin Pharmacol. 2004 Dec;44(12):1398-404
pubmed: 15545311
Child Adolesc Psychiatr Clin N Am. 2014 Jan;23(1):73-82
pubmed: 24231168
Am J Obstet Gynecol. 2005 Feb;192(2):633-9
pubmed: 15696014
J Child Adolesc Psychopharmacol. 2014 Apr;24(3):112-9
pubmed: 24690011
AAPS J. 2014 May;16(3):568-76
pubmed: 24700271
Clin Transl Sci. 2020 Jan;13(1):116-124
pubmed: 31647186
CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):967-972
pubmed: 34288581
Pharmacogenetics. 2000 Jul;10(5):425-38
pubmed: 10898112
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
J Clin Pharmacol. 2001 Jul;41(7):723-31
pubmed: 11452704
Clin Pharmacol Ther. 2016 Jun;99(6):642-50
pubmed: 26660002
Eur J Clin Pharmacol. 2005 Dec;61(11):821-9
pubmed: 16315033
Br J Clin Pharmacol. 2022 Oct;88(10):4267-4284
pubmed: 33733546
J Biol Chem. 2014 Feb 7;289(6):3105-13
pubmed: 24318876
Pharmacogenetics. 1998 Oct;8(5):403-10
pubmed: 9825832
Clin Pharmacol Ther. 2008 Feb;83(2):234-42
pubmed: 17971818
Drug Metab Dispos. 2016 Jul;44(7):916-23
pubmed: 27302933
MMWR Surveill Summ. 2021 Dec 03;70(11):1-16
pubmed: 34855725
Child Adolesc Psychiatry Ment Health. 2008 Sep 15;2(1):24
pubmed: 18793403
Arch Dis Child. 2013 Sep;98(9):737-44
pubmed: 23832061
Eur J Clin Pharmacol. 1999 May;55(3):177-84
pubmed: 10379632
Br J Clin Pharmacol. 2001 Feb;51(2):169-73
pubmed: 11259990
Eur J Clin Pharmacol. 2008 May;64(5):465-75
pubmed: 18202841
Clin Pharmacol Ther. 1997 Oct;62(4):400-7
pubmed: 9357391
J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):159-69
pubmed: 16553536
Biochem Pharmacol. 1997 Jun 1;53(11):1605-12
pubmed: 9264312
J Pers Med. 2018 Apr 17;8(2):
pubmed: 29673183
Clin Pharmacol Ther. 2020 Jan;107(1):154-170
pubmed: 31544239
Pharmacogenomics. 2021 Jun;22(8):447-450
pubmed: 34032507
Pediatr Res. 2006 Dec;60(6):717-23
pubmed: 17065585

Auteurs

J Steven Leeder (JS)

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Andrea Gaedigk (A)

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Krista J Wright (KJ)

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.

Vincent S Staggs (VS)

School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Biostatistics & Epidemiology Core, Division of Health Services and Outcomes Research, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Division of Developmental and Behavioral Sciences, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.

Sarah E Soden (SE)

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Yvonne S Lin (YS)

Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.

Robin E Pearce (RE)

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH